Toggle Main Menu Toggle Search

Open Access padlockePrints

Piloting a scale-up platform for high-quality human T-cells production

Lookup NU author(s): Chaw-Chiea Chang, Dr Yuen Ling Ng, Dr Bernard Loo

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Copyright © 2024 Selvarajan, Teo, Chang, Ng, Cheong, Sivalingam, Khoo, Wong and Loo. Cell and gene therapies are an innovative solution to various severe diseases and unfulfilled needs. Adoptive cell therapy (ACT), a form of cellular immunotherapies, has been favored in recent years due to the approval of chimeric antigen receptor CAR-T products. Market research indicates that the industry’s value is predicted to reach USD 24.4 billion by 2030, with a compound annual growth rate (CAGR) of 21.5%. More importantly, ACT is recognized as the hope and future of effective, personalized cancer treatment for healthcare practitioners and patients worldwide. The significant global momentum of this therapeutic approach underscores the urgent need to establish it as a practical and standardized method. It is essential to understand how cell culture conditions affect the expansion and differentiation of T-cells. However, there are ongoing challenges in ensuring the robustness and reproducibility of the manufacturing process. The current study evaluated various adoptive T-cell culture platforms to achieve large-scale production of several billion cells and high-quality cellular output with minimal cell death. It examined factors such as bioreactor parameters, media, supplements and stimulation. This research addresses the fundamental challenges of scalability and reproducibility in manufacturing, which are essential for making adoptive T-cell therapy an accessible and powerful new class of cancer therapeutics.


Publication metadata

Author(s): Selvarajan V, Teo DBL, Chang C-C, Ng YL, Cheong N, Sivalingam J, Khoo SHG, Wong A, Loo BLW

Publication type: Article

Publication status: Published

Journal: Frontiers in Cell and Developmental Biology

Year: 2024

Volume: 12

Online publication date: 12/07/2024

Acceptance date: 25/06/2024

Date deposited: 06/08/2024

ISSN (electronic): 2296-634X

Publisher: Frontiers Media SA

URL: https://doi.org/10.3389/fcell.2024.1427171

DOI: 10.3389/fcell.2024.1427171

Data Access Statement: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Ministry of Education Translational R&D and Innovation Fund, Singapore (MOE2018-TIF-1-G-023)

Share